Cynthia Pussinen, Chief Executive Officer and Director of Estrella Immunopharma, Inc. (NASDAQ:ESLA), filed a Form 4 on November 4, 2026, disclosing the acquisition of a stock option to purchase 1,000,000 shares of common stock, granted on November 2, 2026.

Key Highlights

  • Grant date: November 2, 2026, with an expiration date of November 2, 2036.
  • Option size: 1,000,000 shares of common stock underlying the stock option (right to buy).
  • Exercise price: $0.43 per share, acquired at a price of $0 (no cost to the reporting person at grant).
  • Vesting schedule: 25% of shares vest on October 25, 2027; the remaining 75% vest in 36 substantially equal monthly installments thereafter, subject to continued service.
  • Plan: Granted under the Issuer's 2023 Omnibus Incentive Plan, approved by the Compensation Committee and the Board of Directors under Rule 16b-3(d).
  • Resulting ownership: 1,000,000 derivative securities beneficially owned directly following the transaction.

Pussinen Option Grant Details: Estrella Immunopharma November 2026

According to the filing, Cynthia Pussinen, who serves as both Chief Executive Officer and Director of Estrella Immunopharma, Inc., acquired a stock option (right to buy) covering 1,000,000 shares of the company's common stock. The transaction date is reported as November 2, 2026, and the transaction code is listed as "A," indicating an acquisition. The exercise price of the option is $0.43 per share, and the price of the derivative security at grant is reported as $0.

The filing states that the option was granted under the Issuer's 2023 Omnibus Incentive Plan and "was approved in advance by the Compensation Committee of the Board of Directors and the Board of Directors in accordance with Rule 16b-3(d)." The option carries an expiration date of November 2, 2036, giving it a ten-year term from the grant date.

As described in the filing's explanation of responses, vesting begins with 25% of the underlying shares becoming exercisable on October 25, 2027. The remaining 75% vest "in 36 substantially equal monthly installments thereafter," contingent on Pussinen's "continued service with the Issuer through each vesting date." Following this transaction, the filing reports that Pussinen directly beneficially owns 1,000,000 derivative securities. No non-derivative securities transactions were reported in Table I of this filing.

What Was Disclosed

Cynthia Pussinen, CEO and Director of Estrella Immunopharma, Inc. (NASDAQ:ESLA), disclosed the grant of a stock option to purchase 1,000,000 shares at $0.43 per share, issued November 2, 2026, under the company's 2023 Omnibus Incentive Plan, with a four-year graduated vesting schedule.